Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Resources

PER Pulse™ Recaps highlight key elements of the Community Practice Connections™: Optimizing Outcomes in HER2-Positive Breast Cancer: Emerging Evidence and Practical Strategies in Early-Stage Treatment Settings online CME activity.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Puma Biotechnology.

Community Practice Connections™: Optimizing Outcomes in HER2-Positive Breast Cancer: Emerging Evidence and Practical Strategies in Early-Stage Treatment Settings

Release Date: May 30, 2017
Expiration Date: May 30, 2018
Media: Internet - based

 

Activity Overview

Optimizing Outcomes in HER2-Positive Breast Cancer: Emerging Evidence and Practical Strategies in Early-Stage Treatment Settings was a satellite symposium held adjunct to the 34th Annual Miami Breast Cancer Conference®, a PER® Legacy International Conference. Although HER2-targeted therapy has resulted in substantial improvements in preventing disease recurrence in the early-stage, HER2-positive (HER2+) breast cancer setting, there remain unmet needs in the field to further improve long-term outcomes for these patients.

This enduring activity features faculty video commentary on key topics presented at the live symposium, including updates on key evidence that informs evolving methods to manage these patients, and to prepare participants to practically apply recent advances in early-stage, HER2+ breast cancer treatment. This activity will also address topics such as landmark and recent key trials conducted in adjuvant settings, the clinical implications of recent findings on novel neoadjuvant and extended adjuvant approaches, and the management of predictable treatment-related toxicities.

Key areas of focus for this activity include:

  • Testing assessments for HER2 status in patients with breast cancer
  • The mechanistic rationale that underlies the development of novel approaches in early-stage, HER2+ breast cancer
  • Analyses of recent clinical trials that have evaluated neoadjuvant and extended adjuvant approaches
  • Evidence on methods to manage and mitigate the impact of treatment-related toxicity in early-stage management settings of HER2+ breast cancer

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Puma Biotechnology.

CME/CE Activity Table of Contents

  • HER2: Biology and Strategies for Optimal Assessment
    Commentary featuring Adam Brufsky, MD, PhD
  • Assessing Long-Term Outcomes and the Need for More Effective Adjuvant Approaches to Early-Stage, HER2+ Breast Cancer
    Commentary featuring Mohammad Jahanzeb, MD
  • Neoadjuvant Strategies for Patients With HER2+ Breast Cancer
    Commentary featuring Debu Tripathy, MD
  • Early-Stage, HER2+ Breast Cancer Management: Exploration of Unresolved Issues/Treatment Questions
    Commentary featuring Kimberly Blackwell, MD

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, surgeons, pathologists, and fellows. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate.

Learning Objectives

Upon completion of this activity, you should be better prepared to:

  • Determine current outcomes with standard adjuvant treatment of HER2+ breast cancer, and identify clinically unmet needs that remain in the field
  • Identify testing that can be utilized to inform clinical decision making for patients with early-stage, HER2+ breast cancer
  • Describe key findings from recent clinical trials conducted in HER2+ breast cancer that have evaluated extended adjuvant approaches
  • Place key findings from clinical trials in the context of best practices that can translated and practically applied to manage early-stage, HER2+ breast cancer

Faculty, Staff, and Planners' Disclosures

Chair

Debu Tripathy, MD
Professor and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
 

Disclosure: Grant/Research Support: Novartis; Consultant: Nektar Therapeutics, Novartis, Puma Biotechnology

Faculty

Kimberly Blackwell, MD
Kimberly L. Blackwell, MD
Professor of Medicine
Duke University Medical Center
Durham, NC
 

Disclosure: Grant/Research Support: Celgene, Genentech, Pfizer, Novartis; Consultant: Advaxis, Bayer, Celgene, Coherus BioSciences, Eli Lilly, Genentech, Incyte Corp, MacroGenics, Merck, Novartis, Pfizer, Pierian Biosciences, Puma, Roche, Sandoz

Adam M. Brufsky, MD, PhD
Professor of Medicine
Associate Chief, Division of Hematology/Oncology
Co-Director, Comprehensive Breast Cancer Center
Associate Director, Clinical Investigation
University of Pittsburgh School of Medicine
Pittsburgh, PA

Disclosure: Consultant: Novartis, Roche, Eisai, Celgene, Lilly, Pfizer, Agendia, Genomic Health, NanoString Technologies, Biotheranostics

Mohammad Jahanzeb, MD, FACP
Medical Director, UM Sylvester Deerfield Campus
Associate Center Director for Community Outreach
Sylvester Comprehensive Cancer Center
University of Miami, Miller School of Medicine
Deerfield Beach, FL

Disclosure: Grant/Research Support: Lilly, AbbVie, Genentech, Novartis; Consultant: Novartis, Genentech

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

CME/CE Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
info@gotoper.com

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise






Become a Member

Forgot Password?
Filter By